<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">625</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2022-21-2-128-130</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Treatment of severe hemophilia A without an inhibitor with emicizumab: 128 a case report</article-title><trans-title-group xml:lang="ru"><trans-title>Случай лечения эмицизумабом тяжелой формы гемофилии А без ингибитора</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1707-2639</contrib-id><name-alternatives><name xml:lang="en"><surname>Andreyeva</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Андреева</surname><given-names>Н. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Natalia A. Andreeva</bold>, Chief External Expert in Pediatric Hematology of the Ministry of Health of the Udmurt Republic, a pediatric oncologist and hematologist at the Outpatient Clinic No. 1 of the Republican Children’s Clinical Hospital of the Ministry of Health of the Udmurt Republic</p><p>79 Lenina St., 426009, Izhevsk</p></bio><bio xml:lang="ru"><p><bold>Андреева Наталья Николаевна</bold>, главный внештатный детский специалист-гематолог Министерства здравоохранения Удмуртской Республики, врач – детский онколог, гематолог Консультативной поликлиники №1 БУЗ УР «Республиканская детская клиническая больница Министерства здравоохранения Удмуртской Республики»</p><p>426009, Ижевск, ул. Ленина, 79</p></bio><email>nataliaizh@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Korolyova</surname><given-names>D. N.</given-names></name><name xml:lang="ru"><surname>Королева</surname><given-names>Д. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Izhevsk</p></bio><bio xml:lang="ru"><p>Ижевск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bogatyryova</surname><given-names>E. N.</given-names></name><name xml:lang="ru"><surname>Богатырева</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Izhevsk</p></bio><bio xml:lang="ru"><p>Ижевск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sergeyeva</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Сергеева</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Izhevsk</p></bio><bio xml:lang="ru"><p>Ижевск</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Penkina</surname><given-names>N. I.</given-names></name><name xml:lang="ru"><surname>Пенкина</surname><given-names>Н. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Izhevsk</p></bio><bio xml:lang="ru"><p>Ижевск</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Children’s Clinical Hospital of the Ministry of Health of the Udmurt Republic</institution></aff><aff><institution xml:lang="ru">БУЗ УР «Республиканская детская клиническая больница Министерства здравоохранения Удмуртской Республики»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Izhevsk State Medical Academy of the Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Ижевская государственная медицинская академия» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-07-08" publication-format="electronic"><day>08</day><month>07</month><year>2022</year></pub-date><volume>21</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>128</fpage><lpage>130</lpage><history><date date-type="received" iso-8601-date="2022-06-25"><day>25</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-06-25"><day>25</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/625">https://hemoncim.com/jour/article/view/625</self-uri><abstract xml:lang="en"><p>   In this article, we report data on the clinical use of emicizumab in a child under 1 year of age with severe hemophilia A without an inhibitor. It was concluded that treatment with emicizumab would be another step toward achieving full control of hemorrhagic syndrome in patients with hemophilia A, especially in children. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.</p></abstract><trans-abstract xml:lang="ru"><p>   В статье представлен клинический случай терапии препаратом эмицизумаб ребенка в возрасте до 1 года с тяжелой формой гемофилии А без ингибитора. Сделан вывод, что терапия эмицизумабом – это еще один шаг на пути к полному контролю над геморрагическим синдромом при тяжелой гемофилии А, особенно у детей. Родители пациента дали согласие на использование информации,ь в том числе фотографий ребенка, в научных исследованиях и публикациях.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hemophilia A</kwd><kwd>severe form of hemophilia A</kwd><kwd>without an inhibitor</kwd><kwd>children</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гемофилия А</kwd><kwd>тяжелая форма гемофилии А</kwd><kwd>без ингибитора</kwd><kwd>дети</kwd></kwd-group><funding-group><funding-statement xml:lang="en">Not specified</funding-statement><funding-statement xml:lang="ru">Не указан</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Гематология: Национальное руководство / Под ред. проф. О. А. Рукавицына. – М.: ГЭОТАР-Медиа, 2017. – 784 с.</mixed-citation><mixed-citation xml:lang="ru">Гематология: Национальное руководство / Под ред. проф. О. А. Рукавицына. – М.: ГЭОТАР-Медиа, 2017. – 784 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Гемофилия: Клинические рекомендации / Национальное гематологическое общество, Национальное общество детских гематологов и онкологов. – М., 2020. – 52 с.</mixed-citation><mixed-citation xml:lang="ru">Гемофилия: Клинические рекомендации / Национальное гематологическое общество, Национальное общество детских гематологов и онкологов. – М., 2020. – 52 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Oldenburg J., Mahlangu J. N., Kim B., Schmitt C., Callghan M. U., Young G., еt al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017; 377 (9): 809–18.</mixed-citation><mixed-citation xml:lang="ru">Oldenburg J., Mahlangu J. N., Kim B., Schmitt C., Callghan M. U., Young G., еt al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017; 377 (9): 809–18.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Mahlangu J., Oldenburg J., Paz-Priel I., Negrier C., Niggli M., Mancuso M. E., et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia Awithout Inhibitors. N Engl J Med 2018; 379 (9): 811–22.</mixed-citation><mixed-citation xml:lang="ru">Mahlangu J., Oldenburg J., Paz-Priel I., Negrier C., Niggli M., Mancuso M. E., et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia Awithout Inhibitors. N Engl J Med 2018; 379 (9): 811–22.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
